BioLife Plasma Services is a subsidiary of Takeda, a global biopharmaceutical company headquartered in Japan. Takeda acquired BioLife in 2019 through its purchase of Shire, which had previously owned the plasma collection company. BioLife operates numerous plasma collection centers worldwide, contributing significantly to the global plasma supply used in the development of life-saving therapies.
Understanding the ownership structure of a major player in the plasma industry provides valuable context for discussions surrounding plasma donation, pharmaceutical development, and healthcare economics. Plasma-derived therapies treat a range of serious health conditions, including immune deficiencies, bleeding disorders, and shock. The acquisition of BioLife by a global pharmaceutical giant like Takeda reflects the growing importance of plasma as a critical resource in modern medicine.
